[Therapy of fungal septicemia and bounds (author's transl)]

Anesth Analg (Paris). 1979 Jan-Feb;36(1-2):13-7.
[Article in French]

Abstract

The authors present the results of therapy in 26 cases of fungal septicemia occurring in a 2,471 patients population with 169 septicemia, over a 9 year period in a surgical intensive care service. An analysis of the etiology, clinical and paraclinical factors confirms the notions classically described in the literature. Three points are particularly insisted upon: 1) The effectiveness of preventive measures; 2) The monitoring of the therapy and its tolerance by means of a simple protocol; 3) The eventual possibility of an haematologic toxicity by flucytosine, the primary and secondary resistances to this anti-fungal agent. The strict application of preventive measures seems to reduce the incidence of fungal septicemia but not to eradicate them. The prognosis of these states remains grave.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amphotericin B / therapeutic use*
  • Candida albicans
  • Candidiasis / drug therapy
  • Cytosine / analogs & derivatives*
  • Drug Tolerance
  • Female
  • Flucytosine / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Mycoses / drug therapy*
  • Postoperative Complications / prevention & control
  • Sepsis / drug therapy*
  • Sepsis / etiology
  • Wound Infection / prevention & control

Substances

  • Amphotericin B
  • Cytosine
  • Flucytosine